Marshall Wace LLP Makes New $2.19 Million Investment in Orthofix Medical Inc. (NASDAQ:OFIX)

Marshall Wace LLP acquired a new stake in shares of Orthofix Medical Inc. (NASDAQ:OFIX - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 165,357 shares of the medical device company's stock, valued at approximately $2,193,000. Marshall Wace LLP owned 0.44% of Orthofix Medical at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Rubric Capital Management LP grew its position in shares of Orthofix Medical by 0.8% during the second quarter. Rubric Capital Management LP now owns 3,694,946 shares of the medical device company's stock worth $48,995,000 after purchasing an additional 29,946 shares in the last quarter. Engine Capital Management LP purchased a new stake in shares of Orthofix Medical during the 4th quarter worth approximately $40,916,000. Paradigm Capital Management Inc. NY boosted its position in shares of Orthofix Medical by 31.3% during the 2nd quarter. Paradigm Capital Management Inc. NY now owns 2,556,100 shares of the medical device company's stock valued at $33,894,000 after acquiring an additional 609,137 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Orthofix Medical by 0.5% in the first quarter. Vanguard Group Inc. now owns 2,008,816 shares of the medical device company's stock valued at $29,168,000 after purchasing an additional 9,150 shares in the last quarter. Finally, Glenview Capital Management LLC bought a new stake in Orthofix Medical in the fourth quarter worth $6,740,000. Hedge funds and other institutional investors own 89.76% of the company's stock.

Orthofix Medical Trading Up 0.3 %

OFIX traded up $0.04 on Friday, hitting $15.29. The company had a trading volume of 159,578 shares, compared to its average volume of 336,502. Orthofix Medical Inc. has a 12-month low of $9.57 and a 12-month high of $17.67. The company has a quick ratio of 1.13, a current ratio of 2.48 and a debt-to-equity ratio of 0.24. The business's fifty day simple moving average is $16.29 and its 200 day simple moving average is $14.82. The company has a market cap of $583.62 million, a PE ratio of -4.52 and a beta of 1.05.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The medical device company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.58). The firm had revenue of $198.62 million for the quarter, compared to the consensus estimate of $195.75 million. Orthofix Medical had a negative net margin of 15.61% and a negative return on equity of 20.68%. Equities research analysts expect that Orthofix Medical Inc. will post -2.13 EPS for the current year.

Orthofix Medical Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.